{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"5.1","value":"4.2"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"2.8","value":"2.6"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"6.8","value":"2.9"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"2.8","value":"2.6"},{"groupId":"OG004","lowerLimit":"1.7","upperLimit":"5.5","value":"3.7"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"3.0","value":"2.2"}]}],"title":"TTF, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"5.4","value":"4.3"},{"groupId":"OG001","lowerLimit":"1.6","upperLimit":"2.8","value":"2.6"},{"groupId":"OG002","lowerLimit":"1.1","upperLimit":"6.8","value":"2.9"},{"groupId":"OG003","lowerLimit":"1.6","upperLimit":"2.8","value":"2.6"},{"groupId":"OG004","lowerLimit":"1.7","upperLimit":"5.5","value":"3.7"},{"groupId":"OG005","lowerLimit":"1.4","upperLimit":"3.0","value":"2.2"}]}],"title":"TTF, 36 months (DCO: Dec 11, 2020)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"22"}],"units":"Participants"}],"description":"Time to treatment failure (TTF) was defined as the time from the date of randomization (the date of the registration for Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD), death due to any cause, or treatment discontinuation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.","id":"OG001","title":"Physician's Choice Irinotecan"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG002","title":"Physician's Choice Paclitaxel"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG003","title":"Physician's Choice Overall"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG004","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG005","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEDIAN","populationDescription":"Time to treatment failure (TTF) was assessed in the Full Analysis Set.","reportingStatus":"POSTED","timeFrame":"From date of randomization to first documentation of PD, death due to any cause, or treatment discontinuation (whichever comes first), up to 36 months postdose","title":"Time to Treatment Failure Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set)","type":"SECONDARY","unitOfMeasure":"months"}